FOLR2 and lung carcinoma: Therefore, we demonstrated the feasibility of using FRβ as a therapeutic target for TAMs in the microenvironment of lung cancer and developed a folate-modified lipoplex comprising a F-PLP delivering a pBIM to target lung cancer.